Ascletis Pharma(01672.HK): Proposed Share Repurchase of Up to HK$300 Million
NewTimeSpace News: On June 30, 2026, Ascletis Pharma(01672.HK) issued a voluntary announcement stating that the Board has resolved to exercise the share repurchase mandate and conduct share repurchases on the open market from time to time in light of market conditions, with a proposed maximum aggregate repurchase amount of HK$300 million.
The Company stated that all repurchases will comply with the terms of the repurchase mandate, the Listing Rules and applicable laws and regulations, and will not cause the public float to fall below the statutory minimum percentage. Repurchased shares may subsequently be cancelled, held as treasury shares, sold or transferred.
NewTimeSpace Disclaimer: All content herein is the original work of NewTimeSpace. Any reproduction, reprinting, or use of this content in any other manner must clearly indicate the source as "NewTimeSpace". NewTimeSpace and its authorized third-party information providers strive to ensure the accuracy and reliability of the data, but do not guarantee the absolute correctness thereof. This content is for reference only and does not constitute any investment advice. All transaction risks shall be borne by the user.
- Ascletis Pharma(01672.HK): Fixed-Dose Combination of GIPR Agonist ASC48 and GLP-1R Agonist ASC30 Selected for Clinical Development
- WK GROUP (02535.HK): Mandatory Unconditional Cash Offer Lapses After Conditions Unmet on 2 October
- ASCLETIS-B (01672.HK): ASC36_35FDC preclinical data presented at EASD 2026
- Hong Kong AI Concept Stock Daily: BIRENTECH Rises 12.23% in a Single Day as the 2026 Apsara Conference Approaches - 20260921
- PALASINO (02536.HK): Independent non-executive director Jiao Jie resigns, ceases to be audit committee member
